Skip to content
SPACListing

Market review

The SPAC market in January 2025

5 IPOs, 2 deals announced, 1 closed, 3 wound up in the U.S. SPAC market in January 2025, with trust sizes, targets and outcomes, compiled from SEC filings.

Published Feb 1, 2025 · Updated Sep 7, 2026 · SPACListing research desk

January 2025 produced 5 IPOs, 2 deals announced, 1 closed, 3 wound up across the U.S. blank-check market. Everything below comes from the filings themselves, and every vehicle named links to its own record.

New vehicles

5 SPACs priced an IPO in January 2025, putting $583.2M into trust between them.

  • Cantor Equity Partners I, Inc. (CEPO), $211.2M
  • Ribbon Acquisition Corp. (RIBB), $38.4M
  • Columbus Acquisition Corp/Cayman Islands (COLA), $27.2M
  • Drugs Made In America Acquisition Corp. (DMAA), $146.8M
  • Stellar V Capital Corp. (Cayman Islands) (SVCC), $159.5M

Deals announced

2 vehicles signed a definitive business-combination agreement. An announcement starts the clock on a proxy, a shareholder vote and a redemption window, and a signed agreement is not a closed one.

  • Black Spade Acquisition II Co, $156.9M
  • Rising Dragon Acquisition Corp. (RDAC), $18.4M

Approved by shareholders

2 combinations went to a vote and passed. At that point the redemption window has run and what remains in trust is what the deal has to work with.

  • Golden Star Acquisition Corp
  • RF Acquisition Corp., $18.1M

Closed

1 de-SPAC completed in January 2025. The shell is gone and the target trades in its place.

  • Chenghe Acquisition I Co., $45.8M

Wound up

3 vehicles ran out of time and returned $42.9M to shareholders. Liquidation is the ordinary outcome for a SPAC that never finds a target, not a failure of the structure.

  • Mars Acquisition Corp., $22.8M
  • Golden Star Acquisition Corp
  • Coliseum Acquisition Corp., $20.1M

Compiled automatically from SEC filings on the day after the month ended. Figures are as filed; where a disclosure could not be reconciled it is left out rather than estimated.

Written from public SEC filings and market practice. Not investment, legal or tax advice, and no substitute for the document in front of you.